
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Warnings of the dangers of isotretinoin use in pregnant women are failing, according to a report by the U.S. Centers for Disease Control and Prevention.